Class / Patent application number | Description | Number of patent applications / Date published |
562503000 | Cyclopentyl (e.g., prostoglandins, etc.) | 6 |
20090118539 | GENERATION OF ENDO- AND/OR EXO-NORBORNENECARBOXALDEHYDE AS AN INTERMEDIATE TO FUNCTIONALIZED NORBORNENES - Embodiments in accordance with the present invention provide for forming essentially pure diastereomers of 5/6-substituted norbornene-type monomers. Further, embodiments in accordance with the present invention encompass polymerizing such diastereomers to form addition or ROMP polymers where a desired exo-/endo-ratio of the diastereomers is provided to the polymerization, such ratio designed to provide a desired ratio of endo-/exo-structured repeating units for a resulting polymer to have desired physical or chemical properties. | 05-07-2009 |
20100041918 | CYCLOPENTENE DIOL MONOACETATE DERIVATIVES - A process for the preparation of organic compounds of formula (I), wherein R | 02-18-2010 |
20100048945 | PROCESS FOR THE ACYLATION OF ORGANIC HYDROXY COMPOUNDS - A process for acylating organic hydroxy compounds, characterized in that the acylation is effected in the presence of a metal oxide which does not carry a catalyst and the use of such metal oxides for acylating organic hydroxy compounds. | 02-25-2010 |
562504000 | Cyclopentyl bonded to -COOR, -CCOOR, or -CCCOOR | 3 |
20120041229 | METHODS FOR MANUFACTURING TETRANOR-PROSTAGLANDIN D, J, E, A AND F METABOLITES - The present invention generally relates to synthetic methods for preparing tetranor-prostaglandin D, J, E, A, and F metabolites. | 02-16-2012 |
20120245380 | Inhibition of Ornithine Aminotransferase for the Treatment of Proliferative Disorders - The invention relates to inhibition of ornithine aminotransferase (OAT) for suppression of tumor cells proliferation. More particularly, the invention relates to methods of treatment of proliferative disorders by the selective inhibition of OAT, and further provides the use of OAT inhibitors, specifically, 5-amino-1,3-hexadienyl-carboxylic acid (Gabaculine), and Gabaculine analogue 8, for compositions and methods for the treatment of proliferative disorders such as hepatocellular carcinoma. The invention further provides methods and kits for the diagnosis of a pathologic proliferative disorder in a mammalian subject, based on determining the level of OAT expressed in a biological sample obtained from a subject. | 09-27-2012 |
20130331604 | (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl)-4-guanidino-2-hydroxy-c- yclopentyl-1-carboxylic acid hydrates pharmaceutical uses thereof - The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza. | 12-12-2013 |